semaglutide and vision loss Popular Diabetes Drug Linked to Rare in New Study Pharma Giants Bet on Patches Subscription Type:3 Months in Full

semaglutide and vision loss Popular Diabetes Drug Linked to Rare in New Study Pharma Giants Bet on Patches Subscription Type:3 Months in Full

Pharma Giants Bet on Next-Generation GLP-1 Treatments to Sustain Growth | S&P Global

M., Rosenlund S., Eriksson J

Patches

Subscription Type:3 Months in Full

or 31.9 kg - 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory) - 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients - 65.3% of 12mg patients dropped below the obesity BMI threshold - 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%) - significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP - no cardiac or liver signals Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time